MicroRNA expression profiles associated with the metastatic ability of MDA‑MB‑231 breast cancer cells

Phannasil,Phatchariya; Phannasil,Phatchariya; Akekawatchai,Chareeporn; Akekawatchai,Chareeporn; Jitrapakdee,Sarawut; Jitrapakdee,Sarawut

doi:10.3892/ol.2023.13926

MicroRNA expression profiles associated with the metastatic ability of MDA‑MB‑231 breast cancer cells

Authors:
- Phatchariya Phannasil
- Chareeporn Akekawatchai
- Sarawut Jitrapakdee
View Affiliations

Affiliations: Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand, Department of Medical Technology, Faculty of Allied Health Sciences, Thammasat University, Pathumtani 12121, Thailand, Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
Published online on: June 22, 2023 https://doi.org/10.3892/ol.2023.13926
Article Number: 339
Copyright: © Phannasil et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is an important worldwide public health concern. The incidence rate of breast cancer increases every year. The primary cause of death is metastasis, a process by which cancer cells spread from a primary site to secondary organs. MicroRNAs (miRs/miRNAs) are small non‑coding RNAs that control gene expression at the post‑transcriptional level. Dysregulation of certain miRNAs is involved in carcinogenesis, cancer cell proliferation and metastasis. Therefore, the present study assessed miRNAs associated with breast cancer metastasis using two breast cancer cell lines, the low‑metastatic MCF‑7 and the highly metastatic MDA‑MB‑231. miRNA array analysis of both cell lines indicated that 46 miRNAs were differentially expressed when compared between the two cell lines. A total of 16 miRNAs were upregulated in MDA‑MB‑231 compared with MCF‑7 cells, which suggested that their expression levels may be associated with the highly invasive phenotype of MDA‑MB‑231 cells. Among these miRNAs, miR‑222‑3p was selected for further study and its expression was confirmed by reverse transcription‑quantitative PCR (RT‑qPCR). Under both non‑adherent and adherent culture conditions, the expression levels of miR‑222‑3p in the MDA‑MB‑231 cell line were higher than those noted in the MCF‑7 cell line under the same conditions. Suppression of endogenous miR‑222‑3p expression in MDA‑MB‑231 cells using a miR‑222‑3p inhibitor resulted in a 20‑40% reduction in proliferation, and a ~30% reduction in migration, which suggested that the aggressive phenotype of MDA‑MB‑231 cells was partly regulated by miR‑222‑3p. Bioinformatic analysis of miR‑222‑3p using TargetScan 8.0, miRDB and PicTar identified 25 common mRNA targets, such as cyclin‑dependent kinase inhibitor 1B, ADP‑ribosylation factor 4, iroquois homeobox 5 and Bcl2 modifying factor. The results of the present study indicated that miR‑222‑3p was potentially associated with the proliferation and migratory ability of the MDA‑MB‑231 cell line.

View Figures

View References

1	Breast cancer, . World Health Organization. 2021.[updated 26 March 2021]. Available from:. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
2	Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO and Gelmon K: Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28:3271–3277. 2010. View Article : Google Scholar : PubMed/NCBI
3	Al-Mahmood S, Sapiezynski J, Garbuzenko OB and Minko T: Metastatic and triple-negative breast cancer: Challenges and treatment options. Drug Deliv Transl Res. 8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
4	Mayer IA, Abramson VG, Lehmann BD and Pietenpol JA: New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clin Cancer Res. 20:782–790. 2014. View Article : Google Scholar : PubMed/NCBI
5	Holliday DL and Speirs V: Choosing the right cell line for breast cancer research. Breast Cancer Res. 13:2152011. View Article : Google Scholar : PubMed/NCBI
6	Xu J, Wu KJ, Jia QJ and Ding XF: Roles of miRNA and lncRNA in triple-negative breast cancer. J Zhejiang Univ Sci B. 21:673–689. 2020. View Article : Google Scholar : PubMed/NCBI
7	Fang H, Xie J, Zhang M, Zhao Z, Wan Y and Yao Y: miRNA-21 promotes proliferation and invasion of triple-negative breast cancer cells through targeting PTEN. Am J Transl Res. 9:953–961. 2017.PubMed/NCBI
8	Chen H, Pan H, Qian Y, Zhou W and Liu X: MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2. Mol Cancer. 17:42018. View Article : Google Scholar : PubMed/NCBI
9	Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, Zhou C and Jiao D: Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol. 36:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
10	Li Z, Meng Q, Pan A, Wu X, Cui J, Wang Y and Li L: MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24. Oncotarget. 8:19455–19466. 2017. View Article : Google Scholar : PubMed/NCBI
11	Amini S, Abak A, Estiar MA, Montazeri V, Abhari A and Sakhinia E: Expression analysis of MicroRNA-222 in breast cancer. Clin Lab. 64:491–496. 2018. View Article : Google Scholar : PubMed/NCBI
12	Falkenberg N, Anastasov N, Rappl K, Braselmann H, Auer G, Walch A, Huber M, Höfig I, Schmitt M, Höfler H, et al: MiR-221/-222 differentiate prognostic groups in advanced breast cancers and influence cell invasion. Br J Cancer. 109:2714–2723. 2013. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
14	Phannasil P, Thuwajit C, Warnnissorn M, Wallace JC, MacDonald MJ and Jitrapakdee S: Pyruvate carboxylase is up-regulated in breast cancer and essential to support growth and invasion of MDA-MB-231 cells. PLoS One. 10:e01298482015. View Article : Google Scholar : PubMed/NCBI
15	McGeary SE, Lin KS, Shi CY, Pham TM, Bisaria N, Kelley GM and Bartel DP: The biochemical basis of microRNA targeting efficacy. Science. 366:eaav17412019. View Article : Google Scholar : PubMed/NCBI
16	Chen Y and Wang X: miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 48(D1): D127–D131. 2020. View Article : Google Scholar : PubMed/NCBI
17	Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin P, Da Piedade I, Gunsalus KC, Stoffel M and Rajewsky N: Combinatorial microRNA target predictions. Nat Genet. 37:495–500. 2005. View Article : Google Scholar : PubMed/NCBI
18	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
19	Akekawatchai C, Roytrakul S, Kittisenachai S, Isarankura-Na-Ayudhya P and Jitrapakdee S: Protein profiles associated with anoikis resistance of metastatic MDA-MB-231 breast cancer cells. Asian Pac J Cancer Prev. 17:581–590. 2016. View Article : Google Scholar : PubMed/NCBI
20	McGuire A, Brown JA and Kerin MJ: Metastatic breast cancer: The potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev. 34:145–155. 2015. View Article : Google Scholar : PubMed/NCBI
21	Song Q, An Q, Niu B, Lu X, Zhang N and Cao X: Role of miR-221/222 in tumor development and the underlying mechanism. J Oncol. 2019:72520132019. View Article : Google Scholar : PubMed/NCBI
22	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007. View Article : Google Scholar : PubMed/NCBI
23	Liu X, Yu J, Jiang L, Wang A, Shi F, Ye H and Zhou X: MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines. Cancer Genomics Proteomics. 6:131–139. 2009.PubMed/NCBI
24	Chun-Zhi Z, Lei H, An-Ling Z, Yan-Chao F, Xiao Y, Guang-Xiu W, Zhi-Fan J, Pei-Yu P, Qing-Yu Z and Chun-Sheng K: MicroRNA-221 and microRNA-222 regulate gastric carcinoma cell proliferation and radioresistance by targeting PTEN. BMC Cancer. 10:3672010. View Article : Google Scholar : PubMed/NCBI
25	Xu K, Liang X, Shen K, Sun L, Cui D, Zhao Y, Tian J, Ni L and Liu J: MiR-222 modulates multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17. Exp Cell Res. 318:2168–2177. 2012. View Article : Google Scholar : PubMed/NCBI
26	Luo F, Zhou J, Wang S, Sun Z, Han Q and Bai C: microRNA-222 promotes colorectal cancer cell migration and invasion by targeting MST3. FEBS Open Bio. 9:901–913. 2019. View Article : Google Scholar : PubMed/NCBI
27	Gao H, Cong X, Zhou J and Guan M: MicroRNA-222 influences migration and invasion through MIA3 in colorectal cancer. Cancer Cell Int. 17:782017. View Article : Google Scholar : PubMed/NCBI
28	Li S, Li Q, Lü J, Zhao Q, Li D, Shen L, Wang Z, Liu J, Xie D, Cho WC, et al: Targeted inhibition of miR-221/222 promotes cell sensitivity to cisplatin in triple-negative breast cancer MDA-MB-231 cells. Front Genet. 10:12782020. View Article : Google Scholar : PubMed/NCBI
29	Said MN, Muawia S, Helal A, Fawzy A, Allam RM and Shafik NF: Regulation of CDK inhibitor p27 by microRNA 222 in breast cancer patients. Exp Mol Pathol. 123:1047182021. View Article : Google Scholar : PubMed/NCBI
30	Ding J, Xu Z, Zhang Y, Tan C, Hu W, Wang M, Xu Y and Tang J: Exosome-mediated miR-222 transferring: An insight into NF-κB-mediated breast cancer metastasis. Exp Cell Res. 369:129–138. 2018. View Article : Google Scholar : PubMed/NCBI
31	Malagobadan S and Nagoor NH: Evaluation of MicroRNAs regulating anoikis pathways and its therapeutic potential. Biomed Res Int. 2015:7168162015. View Article : Google Scholar : PubMed/NCBI
32	Mak CS, Yung MM, Hui LM, Leung LL, Liang R, Chen K, Liu SS, Qin Y, Leung TH, Lee KF, et al: MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 16:112017. View Article : Google Scholar : PubMed/NCBI
33	Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, Bolondi L and Negrini M: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene. 27:5651–5661. 2008. View Article : Google Scholar : PubMed/NCBI
34	Yang Y, Cui H and Wang X: Downregulation of EIF5A2 by miR-221-3p inhibits cell proliferation, promotes cell cycle arrest and apoptosis in medulloblastoma cells. Biosci Biotechnol Biochem. 83:400–408. 2019. View Article : Google Scholar : PubMed/NCBI
35	Huang L, Song F, Sun H, Zhang L and Huang C: IRX5 promotes NF-κB signalling to increase proliferation, migration and invasion via OPN in tongue squamous cell carcinoma. J Cell Mol Med. 22:3899–3910. 2018. View Article : Google Scholar : PubMed/NCBI
36	Xie X, Huang Y, Chen L and Wang J: miR-221 regulates proliferation and apoptosis of ovarian cancer cells by targeting BMF. Oncol Lett. 16:6697–6704. 2018.PubMed/NCBI
37	Cochrane DR, Cittelly DM, Howe EN, Spoelstra NS, McKinsey EL, LaPara K, Elias A, Yee D and Richer JK: MicroRNAs link estrogen receptor alpha status and Dicer levels in breast cancer. Horm Cancer. 1:306–319. 2010. View Article : Google Scholar : PubMed/NCBI
38	Wu Q, Ren X, Zhang Y, Fu X, Li Y, Peng Y, Xiao Q, Li T, Ouyang C, Hu Y, et al: MiR-221-3p targets ARF4 and inhibits the proliferation and migration of epithelial ovarian cancer cells. Biochem Biophys Res Commun. 497:1162–1170. 2018. View Article : Google Scholar : PubMed/NCBI
39	Fuso P, Di Salvatore M, Santonocito C, Guarino D, Autilio C, Mulè A, Arciuolo D, Rinninella A, Mignone F, Ramundo M, et al: Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p hyperexpression as potential predictive biomarkers in early breast cancer patients. J Pers Med. 11:8162021. View Article : Google Scholar : PubMed/NCBI
40	Poloznikov AA, Nikulin SV, Raigorodskaya MP, Fomicheva KA, Zakharova GS, Makarova YA and Alekseev BY: Changes in the metastatic properties of MDA-MB-231 cells after IGFBP6 gene knockdown is associated with increased expression of miRNA genes controlling INSR, IGF1R, and CCND1 genes. Bull Exp Biol Med. 166:641–645. 2019. View Article : Google Scholar : PubMed/NCBI
41	Yi D, Wang R, Shi X, Xu L, Yilihamu Y and Sang J: METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and has-miR-146a-5p expression. Oncol Rep. 43:1375–1386. 2020.PubMed/NCBI
42	Poodineh J, Sirati-Sabet M, Rajabibazl M and Mohammadi-Yeganeh S: MiR-130a-3p blocks Wnt signaling cascade in the triple-negative breast cancer by targeting the key players at multiple points. Heliyon. 6:e054342020. View Article : Google Scholar : PubMed/NCBI
43	Sun S, Ma J, Xie P, Wu Z and Tian X: Hypoxia-responsive miR-141-3p is involved in the progression of breast cancer via mediating the HMGB1/HIF-1α signaling pathway. J Gene Med. 22:e32302020. View Article : Google Scholar : PubMed/NCBI
44	Xiao Y, Humphries B, Yang C and Wang Z: MiR-205 dysregulations in breast cancer: The complexity and opportunities. Noncoding RNA. 5:532019.PubMed/NCBI